RESEARCH ARTICLE

Vertical transmission of SARS-CoV-2: A prospective cross-sectional study from a tertiary center

Selcan Sinaci1 | Doga F. Ocal1 | Banu Seven1 | Ali T. Anuk1 | Berhan Besimoglu1 | Mehmet C. Keven1 | Sule Goncu Ayhan1 | Mustafa S. Akin2 | Cuneyt Tayman2,3 | Huseyin L. Keskin1,3 | Elif G. Yapar Eyi1 | Bedia Dinc3,4 | Ozlem Moraloglu Tekin1,3 | Dilek Sahin1,3

1Department of Obstetrics and Gynecology, Ministry of Health, Ankara City Hospital, Ankara, Turkey
2Division of Neonatology, Department of Pediatrics, Ministry of Health, Ankara City Hospital, Ankara, Turkey
3Ankara City Hospital, University of Health Sciences, Istanbul, Turkey
4Department of Medical Microbiology, Ministry of Health, Ankara City Hospital, Ankara, Turkey

Correspondence
Selcan Sinaci, Department of Obstetrics and Gynecology, Ministry of Health, Ankara City Hospital, 1604th St, No. 9, Cankaya, Ankara 06800, Turkey.
Email: selcansinaci@gmail.com

Abstract
The aim was to investigate the association of the delivery mode and vertical transmission of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) through the samples of vaginal secretions, placenta, cord blood, or amniotic fluid as well as the neonatal outcomes. This cross-sectional study presents an analysis of prospectively gathered data collected at a single tertiary hospital. Sixty-three pregnant women with confirmed coronavirus disease 2019 (COVID-19) participated in the study. Vertical transmission of SARS-CoV-2 was analyzed with reverse transcriptase-polymerase chain reaction (RT-PCR) tests and blood tests for immunoglobulin G (IgG)–immunoglobulin M (IgM) antibodies. All patients were in the mild or moderate category for COVID-19. Only one placental sample and two of the vaginal secretion samples were positive for SARS-CoV-2. Except for one, all positive samples were obtained from patients who gave birth by cesarean. All cord blood and amniotic fluid samples were negative for SARS-CoV-2. Two newborns were screened positive for COVID-19 IgG–IgM within 24 h after delivery, but the RT-PCR tests were negative. A positive RT-PCR result was detected in a neonate whose placenta, cord blood, amniotic fluid, and vaginal secretions samples were negative. He died due to pulmonary hemorrhage on the 11th day of life. In conclusion, we demonstrated that SARS-CoV-2 can be detectable in the placenta or vaginal secretions of pregnant women. Detection of the virus in the placenta or vaginal secretions may not be associated with neonatal infection. Vaginal delivery may not increase the incidence of neonatal infection, and cesarean may not prevent vertical transmission. The decision regarding the mode of delivery should be based on obstetric indications and COVID-19 severity.

KEYWORDS
COVID-19, delivery mode, neonatal outcome, pregnancy, SARS-CoV-2, vertical transmission
INTRODUCTION

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has spread rapidly, creating an important public health problem worldwide. The risk of severe coronavirus disease 2019 (COVID-19) may be higher during pregnancy than in the general population. Available data on infection risks for pregnant women include fetal distress, abortus, preterm birth, low birth weight, and stillbirth. The transmission of SARS-CoV-2 from mother to fetus, a process termed vertical transmission, is still unclear. Existing studies in the literature have reported that vertical transmission is possible, and these studies mostly focus on placental transfer. There is limited information on the existence of SARS-CoV-2 in the female genital tract and this information may be important for evaluating both vertical and sexual transmission. There is no consensus on the delivery mode and optimal time of delivery in COVID-19 infected women. Moreover, the safety of vaginal delivery, or whether cesarean delivery prevents vertical transmission is unclear.

The issue of vertical transmission and the possibility of neonatal infection is a major concern in COVID-19 infected women. In the current study, we aimed to investigate the association of the delivery mode and vertical transmission of SARS-CoV-2 through vaginal secretions, placenta, cord blood, or amniotic fluid, as well as neonatal outcomes.

MATERIALS AND METHODS

Participants characteristics

This prospective study was performed in Ankara City Hospital, Department of Perinatology, Ankara, Turkey, between September 10 and November 23, 2020. Our hospital is one of the leading national pandemic centers which handles approximately 15,000 deliveries yearly, and our department has extensive experience dealing with COVID-19 infected pregnant women.

A total of 63 patients participated in the study (Figure 1). All pregnant women included in the study had positive reverse transcriptase-polymerase chain reaction (RT-PCR) results for SARS-CoV-2 RNA. Maternal age, gravidity, parity, number of living children, previous history of miscarriages, comorbid maternal systemic diseases, gestational age at diagnosis, symptoms, and severity of COVID-19, medications for COVID-19, maternal oxygen support requirement, laboratory test results, a gestational week at the time of delivery, route of delivery, neonatal APGAR scores, birth weight, and whether admission to neonatal intensive care unit was recorded. Clinical classifications according to the COVID-19 severity and treatments for COVID-19 were administered according to the latest national guidelines at the time of admission. During the study period, none of the medical staff had symptoms or tested positive for COVID-19.

Sample collection

Maternal samples

Nasopharyngeal and oropharyngeal swabs were used to identify COVID-19 infection. When the pregnant women were in a sitting position with head and neck support, first the oropharyngeal and then the nasopharyngeal samples were taken by the swab. To ensure adequate sampling, the nasal swab was rotated for a few seconds after reaching the posterior wall of the nasopharynx. Patients with positive RT-PCR test results were followed up for delivery. Chest imaging was performed with radiography in patients with symptoms such as cough or fever.

Placental, umbilical cord, vaginal secretion, and amniotic fluid samples

Placental samples were taken immediately after the delivery of the placenta. Maximum care was taken to avoid contamination of tissues. Approximately 5 cm of tissue was taken, including the umbilical cord, amniochorionic membrane, and placenta. Both vaginal secretion and amnion fluid sampling was performed before the rupture of the membranes. Vaginal samples were taken while the patients were lying on the hospital bed in the delivery room, the swab was inserted through the vagina until reaching posterior fornix and rotated for 3–5 s. To perform amniotic fluid sampling, in patients who had a vaginal delivery, a sterile needle was inserted through the vagina, and 10 cc amnion fluid was carefully taken into the injector in sterile conditions just before the rupture of the membranes, hence before the leaking of the amniotic fluid through the vagina. Similarly, in patients who gave birth with cesarean section, a needle was inserted during the C-section, and 10 cc amnion fluid was obtained in sterile conditions just before the rupture of the membranes. The sterile cover samples were transferred to the molecular virology laboratory in phosphate-buffered saline (PBS) solution within 30 min.

Neonatal samples

Newborns of COVID-19 positive women were tested for RT-PCR. Similar to their mothers, nasopharyngeal and oropharyngeal swabs were used to screen the COVID-19 infection in the newborns. The newborns were stabilized by two nurses to perform nasopharyngeal and oropharyngeal swabs correctly, and then the swabs were taken in the same way as in the mothers. Samples were taken immediately after delivery and repeated 24 h later. The newborns also received a blood test for immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies within 24 h after birth. COVID IgG and IgM antibodies were reported with a single result, not separately, so we evaluated the results of IgG–IgM both together. Neonatal follow-up was made for 14 days with telemedicine.
2.2.4 | Sample transport

All samples were sent to the molecular microbiology laboratory within 2 h at room temperature; placenta tissues in sterile containers containing PBS, amniotic fluid samples in sterile tubes, vaginal swab samples in tubes containing Viral Transport Medium (various manufacturers), and cord blood samples in tubes containing EDTA.

2.2.5 | Tissue lysis

A tissue lysis process was applied to the placenta tissues before nucleic acid isolation. Approximately 2–3 mm$^3$ of placenta tissue was sectioned and digested on a 65°C heat block with 1000 µl of Buffer ATL (Qiagen) and 50 µl of proteinase K (Qiagen) for a minimum of 3 h.

2.2.6 | Nucleic acid isolation

The same procedure was applied to all samples for nucleic acid isolation after tissue lysis. Nucleic acid isolation was performed using the EZ1 Virus Mini Kit v2.0 (Qiagen) with the EZ1 extraction device (Qiagen) according to the manufacturer’s instructions.

2.2.7 | Real-time RT-PCR

SARS-CoV-2 in all samples was detected by the real-time RT-PCR method targeting Orf1ab and N genes. Real-time RT-PCR was performed by using a Coronex COVID-19 RT-qPCR Detection Kit (DS Bio and Nano Technology) with 20 µl reaction containing 5 µl of RNA, 12.5 µl of CORONEX-Covid 19 DS Mix E (RT-qPCR Master mix), and 2.5 µl of CORONEX-Covid 19 DS PP1 (Orf1ab, N and RNP gene, and primer-probe mix). Positive controls for amplification control and no-template control to assess contamination were used in each run. Thermal cycling was performed in a Rotor-Gene Q device (Qiagen) at 48°C for 20 min for reverse transcription, followed by 95°C for 2 min and then 35 cycles of 95°C for 5 s, 60°C for 10 s. Cycle threshold (Ct) values of less than 35 were defined as positive.

2.3 | Statistical analyses

IBM SPSS Statistics version 25.0 (IBM Corp.) was used to perform the statistical analysis. We used descriptive statistical methods. The mean and standard deviation were calculated for continuous and normally distributed variables. Categorical variables were presented as frequencies and percentages.

---

**FIGURE 1** Flow chart of the study participants. IgG, immunoglobulin G; IgM, immunoglobulin M; RT-PCR, reverse transcriptase-polymerase chain reaction.
2.4 Compliance with ethical standards

Before initiating the study, the Ministry of Health of Turkey's approval and ethical board approval (E1-20-602) from Ankara City Hospital Ethical Committee was obtained. The study protocol was performed according to the Declaration of Helsinki principles, and the written informed consent containing the details of the study was obtained from all participants.

3 RESULTS

The demographic characteristics and pregnancy features were presented in Tables 1 and 2. According to COVID-19 severity, all patients were in the mild or moderate category. None of the patients were treated in the intensive care unit. Among 48 PCR-positive women, 25 (52.0%) had no symptoms of COVID-19. Twenty-three (47.9%) patients had nonspecific symptoms such as myalgia, dry cough, sore throat, fatigue, diarrhea, and fever. A total of eight (16.67%) cases had obstetric complications. Eleven (22.9%) patients developed lymphopenia, and thirteen (27.0%) patients had leukocytosis. Platelet count was decreased in five (10.2%) pregnant women. Concentrations of transaminase, C-reactive protein, and D-dimer were elevated in 14 (29.1%), 36 (75%), and 44 (91.6%) patients, respectively. Concentrations of procalcitonin and interleukin-6 were elevated in 18 (37.5%), and 35 (72.9%) pregnant women, respectively. Radiological imaging findings suspicious for COVID-19 were observed on chest radiographs of eight (16.6%) patients. Preterm birth (<37 weeks of gestation) was observed in 17 cases (35.4%). Low birth weight (<2500 g) was observed in nine (18.7%) newborns. In 41 cases (85.4%), 5-min APGAR was greater than seven. Neonatal respiratory distress syndrome occurred in four neonates. Three had tachypnea, two had a low-grade fever but none of them had pneumonia, one died due to pulmonary hemorrhage.

Placental, umbilical cord, amniotic fluid, and vaginal secretion materials of 52 pregnant women infected with SARS-CoV-2 were analyzed by SARS-CoV-2 RNA by RT-PCR test. In four cases, the RT-PCR results were invalid due to failed internal controls as seen in Figure 1. All valid amniotic fluid and umbilical cord samples were negative for SARS-CoV-2. Only one placental sample and two of the vaginal secretion samples were positive for SARS-CoV-2. One of the three positive RT-PCR samples was obtained from a patient who delivered vaginally, and other positive samples were obtained from patients who gave birth by cesarean section. Clinical and laboratory findings of the patients with PCR-positive samples were presented in Table 3. A positive PCR result was encountered in a newborn of a mother whose placental, cord blood, amniotic fluid, and vaginal secretion samples were all negative. Moreover, two newborns were screened positive for COVID-19 IgG–IgM (Table 3).

4 DISCUSSION

The aim of this study was to investigate the vertical transmission of SARS-CoV-2 by evaluating the vaginal secretion, placenta, umbilical cord blood, and amniotic fluid samples with the RT-PCR method and neonatal outcomes. Also, we aimed to detect whether the mode of delivery influences vertical transmission. Our findings suggest that in utero transmission is possible. Among pregnant women who tested positive for SARS-CoV-2, one positive result of placent sample and two positive results of vaginal secretion samples were detected. Among the newborns, only one had a positive RT-PCR result for SARS-CoV-2, but the transmission route was unclear. Also, two newborns were screened positive for COVID-19 IgG–IgM. Similar to the previous reports in the literature, SARS-CoV-2 was not found in amniotic fluid or cord blood.13,14

Potential mechanisms for vertical transmission (viral passage from mother to fetus or newborn) are (i) via the placenta and umbilical cord during intruterine life, (ii) via cervicovaginal secretions during delivery, (iii) via breastfeeding in the postpartum period.15 Maternal–fetal transmission through the placenta begins with the passage of viruses in the maternal circulation, from the uterine arteries to the placenta. Then, the viruses pass into the intervillous space from where they enter into the fetal circulation through the chorionic villi.16 Angiotensin-converting enzyme 2 (ACE2) is the accepted receptor of SARS-CoV-2, which is widely placed on the maternal–fetal interface and plays an essential role in the transmission of the virus.17 Data on the vertical transmission of SARS-CoV-2 is conflicting. In many reports, no evidence of vertical transmission was found regarding various samples such as amniotic fluid, cord blood, neonatal throat glands, placental swabs, genital fluid, and breast milk samples in mothers infected with the virus.13,14,18–20

However, several studies exist in the literature reporting vertical transmission of SARS-CoV-2 through the placenta.7–10 Although some show electronic microscopic changes, some have reported the presence of the SARS-CoV-2 genome in the placentas, especially in the term period.21,22 It is revealed that the risk and rate of viral transmission increases as the gestational week progresses.15 Consistent with the previous reports, we found evidence that SARS-CoV-2 RNA can be found in placentas. Our data showed a term placenta with positive SARS-CoV-2 RNA result in which the pregnancy resulted in a cesarean delivery due to the development of fetal distress. The neonate’s RT-PCR test was negative for SARS-CoV-2. Based on this result, we can say that the detection of SARS-CoV-2 in the placenta does not mean RT-PCR positivity in the newborn.

| Table 1 The demographic characteristics of the participants | Mean ± SD | Median | Min–max |
|-----------------------------------------------------------|-----------|--------|---------|
| Maternal age                                               | 28.1 ± 5.5| 28     | 17–40   |
| Gestational week                                           | 37.2 ± 2.6| 38     | 27–40   |
| Birth weight                                               | 3007.8 ± 657.5 | 3190 | 1370–4180 |
Evidence supporting intrauterine transmission lies in the detection of elevated levels of IgM and IgG against SARS-CoV-2 in newborns. Recently, a positive RT-PCR result and IgM virus-specific antibodies for SARS-CoV-2 were reported in a newborn of a COVID-19 infected mother. It is known that detection of IgM antibodies indicates recent exposure to SARS-CoV-2, while detection of IgG antibodies indicates exposure to the virus some time ago. In our study, two newborns had positive IgG–IgM antibodies, but RT-PCR tests were both negative for SARS-CoV-2 within 24 h after delivery. As the laboratory reported IgG and IgM together as a single result, we could not clearly reveal whether IgG, IgM, or both were positive, but as RT-PCR tests were negative in these two cases, we think that the essentially positive one was IgG. Therefore, we can claim that the newborns encountered SARS-CoV-2 in the womb during perinatal life. However, placental, umbilical cord blood, amniotic fluid, and vaginal secretion samples of these were all negative. The mothers of the IgG–IgM positive neonates had mild-moderate COVID-19, and one of them delivered vaginally. The newborns did not develop COVID-19 symptoms during the 14-day follow-up. On the other hand, the infant with positive RT-PCR for SARS-CoV-2 was followed up in the NICU for 11 days and died due to pulmonary hemorrhage. However, his mother had mild COVID-19 and discharged healthily. As pulmonary hemorrhage is a considerable complication of preterm labor, the underlying cause of neonatal death, in this case, may be due to premature birth rather than the direct effect of COVID-19.

In a recent study involving 10 pregnant women with severe disease, all vaginal sample tested negative for SARS-CoV-2. In a large series on the subject, all cervical exfoliated cells, vaginal fluid, and anal swab samples of the included 35 patients were negative for SARS-CoV-2. This might be explained by the negative expression of ACE2 in the vagina and cervix, which is the SARS-CoV-2 receptor. The strength of our study is the relatively high number (48) of participants and the meticulous prospective analysis of various samples of pregnant women as well as their newborns.

In a retrospective analysis comparing 10 positive pregnant women for SARS-CoV-2 with 53 healthy pregnant women, there were no significant differences in neonatal outcomes between the groups, and all neonates were tested negative for SARS-CoV-2. However, confusing reports keep coming. In a recent case, it was reported that a newborn who was positive for SARS-CoV-2 was delivered vaginally.

### Table 2: Pregnancy features

| Variable          | n (%) |
|-------------------|-------|
| **Gravidity**     |       |
| 1                 | 14 (29.1) |
| 2                 | 20 (41.6) |
| 3                 | 7 (14.5)  |
| 4 and above       | 7 (14.5)  |
| **Parity**        |       |
| 0                 | 18 (37.5) |
| 1                 | 18 (37.5) |
| 2                 | 10 (20.8) |
| 3 and above       | 2 (4.1)  |
| **Living child**  |       |
| 0                 | 19 (39.5) |
| 1                 | 18 (37.5) |
| 2                 | 9 (18.7)  |
| 3 and above       | 2 (4.1)  |
| **Mode of delivery** |     |
| Vaginal           | 10 (20.8) |
| Cesarean          | 38 (79.1) |
| Case 1 (positive placental sample) | Case 2 (positive vaginal secretions sample) | Case 3 (positive vaginal secretions sample) | Case 4 (newborn with positive PCR) | Case 5 (newborn with positive IgG–IgM antibodies) | Case 6 (newborn with positive IgG–IgM antibodies) |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| **Placental sample PCR**         | +                               | −                               | −                               | −                               | −                               |
| **Cord blood sample PCR**        | −                               | −                               | −                               | −                               | −                               |
| **Amniotic fluid sample PCR**    | −                               | −                               | −                               | −                               | −                               |
| **Vaginal secretions sample PCR**| −                               | +                               | +                               | −                               | −                               |
| **Single/twin pregnancy**        | Single                         | Twin                            | Single                          | Single                          | Single                          |
| **Maternal COVID-19 severity**   | Mild                            | Mild                            | Mild                            | Mild                            | Mild                            |
| **Chest imaging**                | −                               | −                               | Bilateral pneumonia             | −                               | Bilateral pneumonia             |
| **Maternal symptom**             | Myalgia, lassitude              | Myalgia, lassitude              | Fever, tachycardia, myalgia, lassitude, dysuria, diarrhea, dry cough | Myalgia, lassitude, fatigue     | Sore throat, fatigue            |
| **Prepregnancy BMI**             | 30                              | 32                              | 30                              | 32                              | 31                              |
| **Lymphocyte (10^3/mm^3)**       | 1000                            | 237                             | 1000                            | 1550                            | 1140                            |
| **Procalcitonin (µg/L)**         | 0.07                            | 0.02                            | 0.33                            | 0.02                            | 0.11                            |
| **CRP (mg/L)**                   | 70                              | 71                              | 23                              | 36                              | 32                              |
| **IL-6 (pg/ml)**                 | 52.1                            | 12.3                            | 16.3                            | 7.30                            | 38.4                            |
| **D-dimer**                      | 4                               | 3.03                            | 1.8                             | 1.6                             | 2.6                             |
| **Obstetric complication**       | −                               | −                               | –                               | PPROM                           | −                               |
| **Comorbid maternal disease**    | FMF, papillary thyroid CA       | −                               | −                               | Factor V Leiden mutation        | −                               |
| **Medication use**               | Colchicine, levothyroxine       | −                               | −                               | LMWH                            | −                               |
| **COVID-19 treatment**           | LMWH                            | LMWH                            | LMWH, ceftriaxone, lopinavir/ritonavir, dexamethasone, piperacillin-tazobactam, nasal oxygen, immunoplasma, hydroxychloroquine, postpartum favipiravir | LMWH, azithromycin             | LMWH, favipiravir, ceftriaxone, nasal oxygen |
| **Gestational age at birth (week)** | 39                              | 34                              | 39                              | 27                              | 39                              |
| **Route of delivery**            | C/S                             | C/S                             | C/S                             | C/S                             | C/S                             | Spontaneous vaginal
**TABLE 3** (Continued)

| Case 1 (positive placental sample) | Case 2 (positive vaginal secretions sample) | Case 3 (positive vaginal secretions sample) | Case 4 (newborn with positive PCR) | Case 5 (newborn with positive IgG–IgM antibodies) | Case 6 (newborn with positive IgG–IgM antibodies) |
|-----------------------------------|---------------------------------------------|---------------------------------------------|-----------------------------------|-----------------------------------------------|-----------------------------------------------|
| C/S indication                    | Fetal distress                              | Worsening COVID-19                          | Fetal distress                    | Worsening COVID-19                            |                                               |
| Fetal gender                      | Female                                       | Male                                        | Male                              | Female                                         | Female                                         |
| Birth weight (g)                  | 3240                                         | 185–2150                                    | 3320                              | 1370                                          | 2800                                          |
|                                   |                                              | 3220                                        |                                   | 3410                                          |                                               |
| APGAR 1st/5th min                 | 8/9                                          | 5/7–7/9                                     |                                   | 6/8                                           | 8/9                                           |
|                                   |                                              | 7/9                                         |                                   | 8/10                                          |                                               |
| Nasopharyngeal PCR of the newborn | −                                            | −                                           | +                                 | −                                             | −                                             |
|                                   |                                              |                                              |                                   |                                               |                                               |
| IgG–IgM antibodies of the newborn | −                                            | −                                           | −                                 | +                                             | +                                             |
|                                   |                                              |                                              |                                   |                                               |                                               |
| Neonatal complication             | −                                            | RDS                                         | −                                 | RDSLBW                                        | −                                             |
|                                   |                                              |                                              |                                   |                                               |                                               |
| NICU                              | −                                            | +                                           | +                                 | −                                             | −                                             |
|                                   |                                              |                                              |                                   |                                               |                                               |
| Neonatal outcome                  | Discharged healthily                         | Discharged healthily on the 7th day          | Discharged healthily              | Died on 11th day due to pulmonary hemorrhage | Discharged healthily                          |
|                                   |                                              |                                              |                                   |                                               | Discharged healthily                          |

Abbreviations: C/S, cesarean section; CA, cancer; CRP, C-reactive protein; FMF, familial Mediterranean fever; IgG, immunoglobulin G; IgM, immunoglobulin M; IL-6, interleukin-6; LBW, low birth weight; LMWH, low molecular weight heparin; NICU, neonatal intensive care unit admission; PCR, polymerase chain reaction; PPROM, preterm premature rupture of membranes; RDS, respiratory distress syndrome.
from a woman whose rectal and fecal swabs were positive for SARS-CoV-2. And they inferred that using prefetal anorectal swabs in pregnant women who tested positive for COVID-19 may reduce the risk of perinatal transmission during vaginal delivery. They also emphasized that even if the swab results were positive, a vaginal delivery could be performed after safety measures were taken. This can be thought of as a limitation of our study in that we did not perform prefetal anorectal sampling in patients who gave birth vaginally. Safety measures include the use of an enema in the second stage of labor which may potentially prevent stool leakage and reduce the amount of viral load at birth. Similarly, perineal cleaning with standard disinfection methods before the second stage of labor and after the engagement of the fetal head may be useful.

To the best of our knowledge, this is the first study examining comprehensive test results of vaginal secretions, placenta, cord blood, or amniotic fluid samples at the same time on pregnant women positive for SARS-CoV-2 and as well as the neonatal outcomes.

5 CONCLUSION

Vertical transmission of SARS-CoV-2 seems possible. However, evidence supporting vertical transmission is still insufficient. We demonstrated that SARS-CoV-2 could be detected in the placenta and vaginal secretions of pregnant women. Contrary to fear, vaginal delivery may not increase the incidence of neonatal infection, and cesarean may not prevent vertical transmission. The decision regarding the mode of delivery should be based on obstetric indications and COVID-19 severity. Although the main spread of the virus is by respiratory droplets, sexual transmission of the virus is another issue that needs to be addressed in further studies. Comprehensive analyses on larger series from multiple specimens are required to evaluate further the neonatal safety of vaginal delivery and possible risk factors of vertical transmission in mothers infected with SARS-CoV-2.

ACKNOWLEDGMENTS

The authors would like to express our gratitude to all healthcare staff for their devoted work for more than one year of the pandemic. Pregnant women and newborns, which is a sensitive population, are carefully protected by the extraordinary courage, high sense of responsibility, excellent medical skills, and tireless work of the healthcare professionals. Authors especially thank Siemens Healthineers Turkey for providing RT-PCR kits for fetal-placental samples as a gift and analyzing the samples.

CONFLICTS OF INTEREST

The authors declare that there are no conflict of interest.

AUTHOR CONTRIBUTIONS

Conceptualization, methodology, literature search, data collection, statistical analysis, and writing the article: Selcan Sinaci. Literature search, statistical analysis and reviewing, and editing the article: Doga F. Ocal. Data collection: Banu Seven, Ali T. Anuk, Berhan Besimoglu, Mehmet C. Keven, Sule Goncu Ayhan, and Mustafa S. Akin. Data extraction and analysis: Cuneyt Tayyam. Conceptualization, methodology, reviewing the article: Huseyin L. Keskin and Elif G. Yaper Eyi. Data analysis and writing the article: Bedia Dinc. Supervision: Ozlem Moraloglu Tekin. Conceptualization, methodology, obtaining ethical approval, reviewing, and editing: Dilek Sahin.

ORCID

Selcan Sinaci http://orcid.org/0000-0003-3118-4036
Doga F. Ocal http://orcid.org/0000-0003-4727-7982
Banu Seven https://orcid.org/0000-0003-4731-4755
Ali T. Anuk https://orcid.org/0000-0001-5437-1008
Berhan Besimoglu https://orcid.org/0000-0003-0376-2513
Mehmet C. Keven http://orcid.org/0000-0003-1866-7295
Sule Goncu Ayhan https://orcid.org/0000-0002-5770-7555
Mustafa S. Akin http://orcid.org/0000-0003-2763-7602
Cuneyt Tayyam http://orcid.org/0000-0002-1861-2262
Huseyin L. Keskin https://orcid.org/0000-0002-2268-3821
Elif G. Yaper Eyi https://orcid.org/0000-0001-7541-9197
Bedia Dinc http://orcid.org/0000-0001-8318-2556
Ozlem Moraloglu Tekin http://orcid.org/0000-0001-8167-3837
Dilek Sahin http://orcid.org/0000-0001-8567-9048

REFERENCES

1. WHO/Europe. Coronavirus disease (COVID-19) outbreak—WHO announces COVID-19 outbreak a pandemic. https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic. Accessed June 7, 2021.
2. Ellington S, Strid P, Tong VT, et al. Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status—United States, January 22-June 7, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:769-775. https://doi.org/10.15585/mmwr.mm6925a1
3. Turan O, Hakim A, Dashraath P, Jeslyn WIL, Wright A, Abdul-Kadir R, Clinical characteristics, prognostic factors, and maternal and neonatal outcomes of SARS-CoV-2 infection among hospitalized pregnant women: a systematic review. Int J Gynecol Obstet. 2020;151(1):7-16. https://doi.org/10.1002/ijgo.13329
4. Dubey P, Reddy SY, Manuel S, Dwivedi AK. Maternal and neonatal characteristics and outcomes among COVID-19 infected women: an updated systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2020;252:490-501. https://doi.org/10.1016/j.ejogrb.2020.07.034
5. Halcic-Ozturk F, Ocal FD, Aydin S, et al. Investigating the risk of maternal-fetal transmission of SARS-CoV-2 in early pregnancy. Placenta. 2021;106:25-29. https://doi.org/10.1016/j.placenta.2021.02.006
6. Abdelazim IA, AbuFaza M, Al-Munaifi S. COVID-19 positive woman presented with preterm labor: case report. Gynecol Obstet Reprod Med. 2021;1-3.
7. Mahyuddin AP, Kanneganti A, Wong JIL, et al. Mechanisms and evidence of vertical transmission of infections in pregnancy including SARS-CoV-2. Prenat Diagn. 2020;40(13):1655-1670. https://doi.org/10.1002/pd.5765
8. Patane L, Morotti D, Giunta MR, et al. Vertical transmission of coronavirus disease 2019: severe acute respiratory syndrome coronavirus 2 RNA on the fetal side of the placenta in pregnancies with
coronavirus disease 2019-positive mothers and neonates at birth. Am J Obstet Gynecol MFM. 2020;2(3):100145. https://doi.org/10.1016/j.ajogmf.2020.100145

9. Vivanti AJ, Vauloup-Fellous C, Prevot S, et al. Transplacental transmission of SARS-CoV-2 infection. Nat Commun. 2020;11(1):3572. https://doi.org/10.1038/s41467-020-17436-6

10. Hosier H, Farhadian SF, Morotti RA, et al. SARS-CoV-2 infection of the placenta. J Clin Invest. 2021;130(9):4947-4953. https://doi.org/10.1172/JCI139569

11. Sahin D, Tanacan A, Erol SA, et al. Updated experience of a tertiary pandemic center on 533 pregnant women with COVID-19 infection: a prospective cohort study from Turkey. Int J Gynaecol Obstet. 2021;152(3):328-334. https://doi.org/10.1002/ijo.13460

12. Turkish Ministry of Health. General Directorate of Public Health, COVID-19 (SARS-CoV-2 infection) Guideline, Scientific Committee Report: https://covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf?type=file. Accessed August 21, 2020.

13. Zhu H, Wang L, Fang C, et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. Transl Pediatr. 2020;9(1):51-60. https://doi.org/10.21037/tp.2020.02.06

14. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020,395(10226):809-815. https://doi.org/10.1016/S0140-6736(20)30360-3

15. Silasi M, Cardenas I, Racicot K, Kwon J-Y, Aldo P, Mor G. Viral infections during pregnancy. Am J Reprod Immunol. 2015;73(3):199-213. https://doi.org/10.1111/aji.12355

16. Schwartz DA, Dhaliwal A. Infections in pregnancy with Covid-19: report of two cases. BMJ Pregnancy Childbirth. 2020;20(1):580. https://doi.org/10.1186/s12884-020-03281-4

17. World Health Organization. Management of severe acute respiratory infection when COVID-19 is suspected. https://www.who.int/publications/i/item/10665-332299. Accessed June 7, 2021.

18. Royal College of Obstetricians & Gynaecologists. Coronavirus (COVID-19) infection and pregnancy. 2020. https://www.rco.org.uk/en/guidelinesresearch/services/guidelines/coronavirus/pregnancy. Accessed April 23, 2021.

19. Carosso A, Cosma S, Serafini P, Benedetto C, Mahmood T. How to reduce the potential risk of vertical transmission of SARS-CoV-2 during vaginal delivery? Eur J Obstet Gynecol Reprod Biol. 2020;250:246-249. https://doi.org/10.1016/j.ejogrb.2020.04.065

20. Qiu L, Liu X, Xiao M, et al. SARS-CoV-2 is not detectable in the vaginal fluid of women with severe COVID-19 infection. Clin Infect Dis. 2020;71(15):813-817. https://doi.org/10.1093/cid/ciaa375

21. Cui P, Chen Z, Wang T, et al. Severe acute respiratory syndrome coronavirus 2 detection in the female lower genital tract. Am J Obstet Gynecol. 2020;223(1):131-134. https://doi.org/10.1016/j.ajo.2020.04.038

22. Uhlén M, Fagerberg L, Hallström BM, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419. https://doi.org/10.1126/science.1260419

23. Liao J, He X, Gong Q, Yang L, Zhou C, Li J. Analysis of vaginal delivery outcomes among pregnant women in Wuhan, China during the COVID-19 pandemic. Int J Gynaecol Obstet. 2020;150(1):53-57. https://doi.org/10.1002/ijgo.13188

24. Carosso A, Cosma S, Borella F, et al. Pre-labor anorectal swab for SARS-CoV-2 in COVID-19 pregnant patients: is it time to think about it? Eur J Obstet Gynecol Reprod Biol. 2020;249:98-99. https://doi.org/10.1016/j.ejogrb.2020.04.023

How to cite this article: Sinaci S, Ocal DF, Seven B, et al. Vertical transmission of SARS-CoV-2: A prospective cross-sectional study from a tertiary center. J Med Virol. 2021;1-9. https://doi.org/10.1002/jmv.27128